Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket

Cell

Volumn 99, Issue 1, 1999, Pages 103-115

  Eckert, Debra M ^a   Malashkevich, Vladimir N ^a   Hong, Lily H ^a   Carr, Peter A ^a   Kim, Peter S ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL FUSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033214895     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)80066-5     Document Type: Article

References (50)

1. Berger, E.A., Murphy, P.M., and Farber, J.M. (1999). Chemokine receptors as HIV-1 coreceptors: Role in viral entry, tropism and disease. Annu. Rev. Immunol. 17, 657-700.
2. Blacklow, S.C., Lu, M., and Kim, P.S. (1995). A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry 34, 14955-14962.
3. Bovey, F.A. (1988). Nuclear Magnetic Resonance Spectroscopy (San Diego, CA: Academic Press).
4. Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. (1998). Crystallography and NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905-921.
5. Cao, J., Bergeron, L, Helseth, E., Thali, M., Repke, H., and Sodroski, J. (1993). Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 72, 2747-2755.
6. Cavanagh, J., and Rance, M. (1993). Suppression of cross-relaxation effects in TOCSY spectra via a modified DIPSI-2 mixing sequence. J. Magn. Reson. Ser. A 105, 328.
7. Cavanagh, J., Fairbrother, W.J., Palmer, A.G., and Skelton, N.J. (1996). Protein NMR Spectroscopy: Principles and Practice (San Diego, CA: Academic Press).
8. CCP4 (1994). The CCP4 suite: Programs for protein crystallography. Acta. Crystallogr. D 50, 760-763.
9. Chan, D.C., and Kim, P.S. (1998). HIV entry and its inhibition. Cell 93, 681-684.
10. Chan, D.C., Fass, D., Berger, J.M., and Kim, P.S. (1997). Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273.
11. Chan, D.C., Chutkowski, C.T., and Kim, P.S. (1998). Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA 95, 15613-15617.
12. Chen, S.S.-L, Lee, C.-N., Lee, W.-R., McIntosh, K., and Lee, T.-H. (1993). Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J. Virol. 67, 3615-3619.
13. Chen, B.K., Saksela, K., Andino, R., and Baltimore, D. (1994). Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J. Virol. 68, 654-660.
14. Chen, C.-H., Matthew, T.J., McDanal, C.B., Bolgnesi, D.P., and Greenberg, M.L. (1995). A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: Implication for viral fusion. J. Virol. 69, 3771-3777.
15. Crick, F.H. C. (1953). The packing of α-helices: Simple coiled coils. Acta. Crystallogr. 6, 689-697.
16. Dubay, J.W., Roberts, S.J., Brody, B., and Hunter, E. (1992). Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J. Virol. 66, 4748-4756.
17. Ql, a trimeric coiled coil with buried polar residues. J. Mol. Biol. 284, 859-865.
18. Edelhoch, H. (1967). Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6, 1948-1954.
19. Fields, C.G., Lloyd, D.H., Macdonald, R.L., Otteson, K.M., and Noble, R.L. (1991). HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept. Res. 4, 95-101.
20. Furuta, R.A., Wild, C.T., Weng, Y., and Weiss, C.D. (1998). Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5, 276-279.
21. Harbury, P.B., Tidor, B., and Kim, P.S. (1995). Repacking protein cores with backbone freedom: Structure prediction for coiled coils. Proc. Natl. Acad. Sci. USA 92, 8408-8412.
22. Hendrickson, W.A. (1991). Determination of macromolecular structures from anomalous diffraction of synchrotron radiation. Science 254, 51-58.
23. Herskowitz, I. (1987). Functional inactivation of genes by dominant negative mutations. Nature 329, 219-222.
24. Hooft, R.W., Vriend, G., Sander, C., and Abola, E.E. (1996). Errors in protein structures. Nature 381, 272.
25. Jiang, S., Lin, K., Strick, N., Neurath, A.R. (1993). HIV-1 inhibition by a peptide. Nature 365, 113.
26. Jones, T.A., Zou, J.W., Cowan, S., and Kjeldgaard, M. (1991). Improved methods for binding protein models in electron density maps and the location of errors in these methods. Acta. Crystallogr. D 47, 110-119.
27. Jones, P.L., Korte, T., and Blumenthal, R. (1998). Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J. Biol. Chem. 273, 404-409.
28. Kilby, J.M., Hopkins, S., Venetta, T.M., DiMassimo, B., Cloud, G.A., Lee, J.Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302-1307.
29. Kimpton, J., and Emerman, M. (1992). Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66, 2232-2239.
30. King, D.S., Fields, C.G., and Fields, G.B. (1990). A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int. J. Pep. Prot. Res. 36, 255-266.
31. Kozarsky, K., Penman, M., Basiripour, L., Haseltine, W., Sodroski, J., and Krieger, M. (1989). Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein. J. Acquir. Immune Defic. Syndr. 2, 163-169.
32. Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J., and Hendrickson, W.A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659.
33. LaCasse, R.A., Follis, K.E., Trahey, M., Scarborough, J.D., Littman, D.R., and Nunberg, J.H. (1999). Fusion-competent vaccines: Broad neutralization of primary isolates of HIV. Science 283, 357-362.
34. Lu, M., and Kim, P.S. (1997). A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biol. Struct. Dyn. 15, 465-471.
35. Lu, M., Blacklow, S.C., and Kim, P.S. (1995). A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2, 1075-1082.
36. Malim, M.H., Hauber, J., Le, S.-Y., Maizel, J.V., and Cullen, B.R. (1989). The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338, 254-257.
37. Munoz-Barroso, I., Durell, S., Sakaguchi, K., Appella, E., and Blumenthal, R. (1998). Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell Biol. 140, 315-323.
38. Osapay, K., and Case, D.A. (1991). A new analysis of proton chemical shifts in proteins. J. Am. Chem. Soc. 113, 9436-9444.
39. Otwinowski, Z. (1993). Oscillation data reduction program. In Data Collection and Processing, L. Sawer, N. Isaacs, and S. Bailey, eds. (Warrington, UK: SERC Daresbury Laboratory), pp. 55-62.
40. Rimsky, L.T., Shugars, D.C., and Matthews, T.J. (1998). Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72, 986-993.
41. Schumacher, T.N.M., Mayr, L.M., Minor, D.L., Milhollen, M.A., Burgess, M.W., and Kim, P.S. (1996). Identification of D-peptide ligands through mirror-image phage display. Science 271, 1854-1857.
42. Shuker, S.B., Hajduk, P.J., Meadows, R.P., and Fesik, S.W. (1996). Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534.
43. Singh, M., Berger, B., and Kim, P.S. (1999). LearnCoil-VMF: Computational evidence for coiled-coil-like motifs in many viral membranefusion proteins. J. Mol. Biol. 290, 1031-1041.
44. Tan, K., Liu, J., Wang, J.-H., Shen, S., and Lu, M. (1997). Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 94, 12303-12308.
45. Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J., and Wiley, D.C. (1997). Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430.
46. Weng, Y., and Weiss, C.D. (1998). Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 72, 9676-9682.
47. Wild, C.T., Shugars, D.C., Greenwell, T.K., McDanal, C.B., and Matthews, T.J. (1994). Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA 91, 12676-12680.
48. Wild, C.T., Greenwell, T., Shugars, D., Rimsky-Clarke, L., and Matthews, T. (1995). The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retroviruses 11, 323-325.
49. Wrighton, N.C., Farrell, F.X., Chang, R., Kashyap, A.K., Barbone, F.P., Mulcahy, L.S., Johnson, D.L., Barrett, R.W., Jolliffe, L.K., and Dower, W.J. (1996). Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273, 458-463.
50. Zapp, M.L., and Green, M.R. (1989). Sequence-specific RNA binding by the HIV-1 Rev protein. Nature 342, 714-716.